XM无法为美国居民提供服务。

Amplifon trims margin forecast as higher marketing costs weigh



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-Amplifon trims margin forecast as higher marketing costs weigh</title></head><body>

Writes through with details on outlook, results and context

Oct 30 (Reuters) -Italian hearing aid company Amplifon AMPF.MI slightly lowered its annual margin guidance on Wednesday, after the metric was hit by higher marketing costs in Europe in the third quarter.

The company said it expected its recurring core profit margin to be broadly in line with 2023, when it posted a margin of 24%. It had previously forecast a margin of around 24.3% for this year.

Its third-quarter core profit margin was 20.3% of revenue, down 40 basis points from last year due to lower operating leverage and higher marketing investments to overcome market softness in the Europe, Middle East and Africa (EMEA) region.

Revenue grew 8% at constant exchange rates to 567.6 million euros ($613.75 million), driven by a 15.3% rise in the Americas, Amplifon's second biggest market that generates about 22% of its total sales.

Its biggest market, EMEA, saw slower 3.8% revenue growth due to a "still soft European market", Amplifon said.

"We continued along our revenue growth path thanks to an above-market organic performance and the significant contribution of acquisitions," CEO Enrico Vita said in the statement.

However, recurring net profit slumped 25.5% to 17.5 million euros due to increased financial expenses and higher depreciation and amortization following acquisitions.

Shares in Amplifon were down 2.9% at 1300 GMT, little changed from before the report was published.

Tech-driven competition in the hearing aid sector is intensifying after Switzeland's Sonova SOON.S launched a first-in-market hearing device utilising real-time AI, and Apple AAPL.O received U.S. approval for software that it said could transform its headphones into a personalized hearing aid.

Analysts have however said that Apple's move was not a concern for hearing aid players as over-the-counter devices target different population than prescription-based aids.

The Milan-based company confirmed its full-year revenue guidance for high single-digit percentage growth at constant exchange rates.

($1 = 0.9248 euros)



Reporting by Alberto Chiumento in Gdansk; editing by Milla Nissi

</body></html>

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明